
My views as a non-native speaker medical writer

ANGELA GARCIA PEREZ, PHD


My journey into Medical Writing...





What difficulties I faced as a non-native speaker

- Some technical and scientific terminology
- Public speaking was a bigger challenge
- Some employers look for native-speakers



ORIGINAL ARTICLE FREE PREVIEW

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, M.D. M.D., György L

Ρ

S

Abstract

[:]lorian Huemer, Study Group*

BACKGROUND Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.

METHODS We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1, or no additional clinical benefit. The two primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat population.

"I also believe that students should learn:

- how to write different publications and documents
- different styles addressed to different audiences and situations
- a logical way of thinking and presenting information
- how the business works, the big picture. "



Thanks for listening !